Surrozen (SRZN) announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent families pending in the U.S. and other countries, five patent families pending in the U.S. only, two pending PCT applications, and four patent families with pending U.S. provisional applications, and has two in-licensed patent families related to the Wnt pathway and its modulation. In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 related to its SWAPTM technology. The patent covers tetravalent, multi-specific Wnt surrogates comprised of: two Frizzled binding regions that specifically bind to two Fzd receptors, wherein each of the two Fzd binding regions comprises an antibody or antigen-binding fragment of the antibody; and two LRP5/6 binding regions that specifically bind to a Low-density lipoprotein receptor-related protein 5 and/or a LDL receptor-related protein 6, wherein each of the two LRP5/6 binding regions comprises an antibody or antigen-binding fragment of the antibody, and wherein each of the two LRP5/6 binding regions is fused to one of the two Fzd binding regions via a linker moiety.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
- Surrozen’s Strategic Focus on Wnt Pathway and Promising Pipeline Earns Buy Rating
- Surrozen, Inc. Reports Q1 2025 Financial Results
- Surrozen files to sell 5.21M shares of common stock for holders
- Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating
- Surrozen Focuses on Ophthalmology Amid Financial Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue